- Global Pharma News & Resources

Form 8-K Filed by Rosecliff Acquisition Corp I

Form 8-K Filed by Rosecliff Acquisition Corp I

LONDON, U.K. AND DALLAS, TX, U.S. – Spectral MD Holdings, Ltd. (AIM: SMD), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, notes the Form 8-K filing (the “Form 8-K”) by Rosecliff Acquisition Corp. I (“Rosecliff”, Nasdaq: RCLF) on April 17, 2023 which is available to view on the U.S. Securities and Exchange Commission (the “SEC”) website here and is reproduced in full below.

On April 11, 2023, Spectral MD announced that it had entered into a business combination agreement to combine with Rosecliff, a special purpose acquisition company listed on Nasdaq (the “Transaction”). The Form 8-K contains summaries of specific, but not all, terms of the business combination agreement and certain ancillary agreements. The Form 8-K filed by Rosecliff was made to ensure compliance with SEC disclosure requirements in relation to the Transaction. Subsequently, this announcement is being made by the Company to ensure that all publicly available information regarding the Transaction and contained in the Form 8-K is available to the market.

The Transaction is expected to be completed in Q3 2023, subject to, among other things, the approval by Rosecliff stockholders and Spectral MD shareholders and the satisfaction or waiver of other customary closing conditions.

The Company will release further updates in relation to the Transaction as and when appropriate.

Editor Details

Last Updated: 19-Apr-2023